Optimer gets positive results from 2nd pivotal phase-3 study of fidaxomicin in clostridum difficile infection
Tuesday, February 09, 2010 18:00 IST San Diego, California
Optimer Pharmaceuticals, Inc announced positive top-line results from the second of two pivotal phase-3 trials evaluating the safety and efficacy of fidaxomicin (OPT-80) in patients with Clostridium difficile Infection (CDI).
